Clinical Trial Update: Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating long-acting growth hormone MOD-4023 in children with growth hormone deficiency reported safety and efficacy results in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• MOD-4023 (long-acting growth hormone)

Snippet

Sponsor: OPKO Health, Inc. | Conditions: Pediatric Growth Hormone Deficiency | Phase 3 | Status: COMPLETED | Results posted: 2021-06-25